As of January 22, 2025, Sera Prognostics (SERA) has a market cap of $0.22 billion USD. According to our data, Sera Prognostics is ranked No.7016 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.22 B |
-17.54%
|
Dec 31, 2024 | $0.27 B |
36.12%
|
Dec 29, 2023 | $0.20 B |
374.60%
|
Dec 30, 2022 | $41.33 M |
-81.66%
|
Dec 31, 2021 | $0.23 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Natera
NTRA
|
$22.70 B |
-0.001 M
|
USA
|
Myriad Genetics
MYGN
|
$1.12 B |
-0.000 M
|
USA
|
Guardant Health
GH
|
$5.83 B |
0.000 M
|
USA
|
Exact Sciences
EXAS
|
$10.14 B |
0.000 M
|
USA
|
Illumina
ILMN
|
$22.26 B |
0.000 M
|
USA
|
NeoGenomics
NEO
|
$1.86 B |
0.000 M
|
USA
|
Fulgent Genetics
FLGT
|
$0.52 B |
-0.000 M
|
USA
|
CareDx
CDNA
|
$1.24 B |
-0.000 M
|
USA
|
Veracyte
VCYT
|
$3.34 B |
-0.000 M
|
USA
|
Adaptive Biotechnologies
ADPT
|
$1.18 B |
0.000 M
|
USA
|
Pacific Biosciences
PACB
|
$0.53 B |
-0.000 M
|
USA
|
10x Genomics
TXG
|
$1.97 B |
0.229 B
|
USA
|
Market Cap | = | SERA Stock Price | * | SERA Shares Outstanding |
= | $6.52 | * | 32.80 M | |
= | $0.22 B |